Minerva Neurosciences Inc

NASDAQ:NERV  
1.35
-0.06 (-4.26%)
Regulatory, Earnings Announcements

Minerva Neurosciences Reports Update On Roluperidone for Treatment of Negative Symptoms of Schizophrenia

Published: 09/30/2021 13:58 GMT
Minerva Neurosciences Inc (NERV) - Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia.
Minerva Neurosciences Inc - Study Met All Key Pharmacokinetic (pk) Objectives and Data Demonstrate Bioequivalence Across Various Formulations.
Revenue is expected to be $0.25 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $0.33 Million
Next Quarter EPS Guidance is expected to be -$0.23

More details on our Analysts Page.